Targets › ERCC1
6 programs from 6 companies in 16 trials: 9 Phase 4, 5 Phase 2, 2 Phase 3; Oncology, Cardiovascular, Immunology; next expected readout Dec 2026.
[Isoform 1]: Non-catalytic component of a structure-specific DNA repair endonuclease responsible for the 5'-incision during DNA repair. Responsible, in conjunction with SLX4, for the first step in the repair of interstrand cross-links (ICL). (UniProt, P07992)
Open in Phaseline: the race on ERCC1, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| Bausch Health Americas | Clindamycin Bacterial 70S ribosome inhibitor | ERCC1, ERCC2 | Phase 4 | Acne Vulgaris; Skin Infection; Infection Control / Methods; Surgical Site Infection … | Dec 2027 |
| Sun Yat-sen University | mFOLFOXIRI Multi-drug chemotherapy regimen: oxaliplatin (platinum-based DNA crosslinker), irinotecan | TOPO1, TOPO2A, ERCC1 | Phase 3 | Colon Cancer Stage II | Dec 2026 |
| Ruijin Hospital | Oxaliplatin plus S-1 Platinum-based DNA crosslinking agent combined with fluoropyrimidine antimetabolite | ERCC1 | Phase 3 | Gastric Cancer (GC); Gastric or Esophagogastric Junction Adenocarcinoma | Apr 2028 |
| Peking Union Medical College Hospital | GC Combination of gemcitabine and cisplatin | RRM1, RRM2, DCK, ERCC1 | Phase 2 | Biliary Tract Neoplasms Immunotherapy | Jan 2027 |
| Shandong Cancer Hospital and Institute | NALIRIFOX Combination chemotherapy with liposomal irinotecan (topoisomerase I inhibitor), oxaliplati | TOP1, ERCC1 | Phase 2 | Pancreatic Cancer | Oct 2028 |
| Institut du Cancer de Montpellier - Val d'Aurelle | modified FOLFIRINOX regimen Combination chemotherapy: irinotecan (topoisomerase I inhibitor), oxaliplatin (platinum cr | TOPO1, TOPO2A, ERCC1 | Phase 2 | Locally Advanced Malignant Neoplasm | Sep 2029 |
Acne Vulgaris (2) Skin Infection (1) Infection Control / Methods (1) Surgical Site Infection (1) Endocarditis Infective (1) Wisdom Tooth Removal (1) Cat Bite (1) Staphylococcus Aureus Bacteremia (1) Aortic Surgery (1) Pancreatic Cancer (1) Colon Cancer Stage II (1) Biliary Tract Neoplasms Immunotherapy (1)
small molecule (4)
Bausch Health Americas (1) Shandong Cancer Hospital and Institute (1) Sun Yat-sen University (1) Peking Union Medical College Hospital (1) Ruijin Hospital (1) Institut du Cancer de Montpellier - Val d'Aurelle (1)
TOPO1 (2) TOPO2A (2) ERCC2 (1) TOP1 (1) RRM1 (1) RRM2 (1) DCK (1)
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.